- About
- Expertise
-
Services
- Testing Services Overview
- Research Models
- GLP Studies & FDA Assistance
- Physician & Clinical Bio-Skills Training
- Cadaver Testing & Training
- Histopathology & Analytical Testing
- Alprazolam (Xanax)
- Armodafinil (Nuvigil)
- Carisoprodol (Soma)
- Exemestane (Aromasin)
- Ivermectin (Stromectol)
- Letrozole (Femara)
- Oseltamivir (Tamiflu)
- Prednisone (Deltasone)
- Pregabalin (Lyrica)
- Sumatriptan (Imitrex)
- Tazarotene (Tazorac)
- Zolpidem (Ambien)
- Zopiclone (Imovane)
- Support
- News/Events
- Blog
- Contact
Services
Purchase Zopiclone (Imovane) tablets online
How and where to order Imovane (Zopiclone) 7.5 mg tablets online:
Shop 1: MEDS DIRECT SHOP
Shop 2: MEDSTORE ONLINE
Prices: from $1.46 per pill
Discount: 5% coupon: 5off_2021 (for Shop 2 only)
Forms: Zopiclone 7.5 mg tablets, Zopisign 10 mg tablets
Quantity: 30, 60, 90, 120, 180 pills
Type: Zopiclone brand, Zopisign brand, Imovane generic
Payment: Visa, Mastercard, AmEx, eCheck, Bitcoin
Delivery: Registered airmail, international delivery service
Shipping: USA, UK, Canada, Australia, Belgium, France, Greece, Ireland, Italy, Spain
Zopiclone (trade names include Imovane, Apo-Zopiclone, Datolan, Dom-Zopiclone, Imoclone, Pro-Zopiclone, Limovan, Mylan-Zopiclone, Optidorm, PMS-Zopiclone, Sedorm, Ran-Zopiclone, Rhovane, Sandoz Zopiclone, Zopiclon CT-Arzneimittel, Imozop, Zopiclon Ratiopharm, Zopiclona Genfar Laboratorios, Zimovane, Zopiclone Actavis, Somnol, Zopiclone Teva, Zopiklon Mylan, Zopivane) is a sedative and hypnotic medication from benzodiazepine related drugs pharmacological group. This medicine is used for the treatment of insomnia, short-term and symptomatic relief of various sleep disturbances. It can help with difficulty falling asleep, frequent wake-ups during the night, or early morning awakenings. Zopiclone also has sedative, anxiolytic, central muscle-relaxing, anticonvulsant and amnesic properties.
Related medications:
Pharmacological and medical categories:
ATC codes:
ICD-10 codes:
Indications and usage:
Zopiclone (Imovane) is indicated for the short-term treatment and symptomatic relief of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakenings.
Treatment with zopiclone should usually not exceed 7-10 consecutive days. Use for more than 2-3 consecutive weeks requires complete re-evaluation of the patient. Prescriptions for zopiclone should be written for short-term use (7-10 days) and it should not be prescribed in quantities exceeding a 1-month supply.
The use of hypnotics should be restricted for insomnia where disturbed sleep results in impaired daytime functioning.
Dosage and administration:
Dosage forms and strengths:
Imovane (Zopiclone) tablets 7.5 mg.
Overdosage:
Signs and symptoms:
Overdose by zopiclone pills is usually manifested by varying degrees of central nervous system depression ranging from drowsiness to coma according to the quantity ingested. In mild cases, symptoms include drowsiness, confusion, and lethargy; in more severe cases, symptoms may include ataxia, hypotonia, hypotension, methaemoglobinaemia, respiratory depression, and coma. Overdose should not be life threatening unless combined with other CNS depressants, including alcohol. Other risk factors, such as the presence of concomitant illness and the debilitated state of the patient, may contribute to the severity of symptoms and very rarely can result in fatal outcome.
In voluntary or accidental cases of zopiclone overdosage involving doses up to 340 mg, the principal effects reported were prolonged sleep, drowsiness, lethargy and ataxia.
Recommended treatment:
Symptomatic and supportive treatment in adequate clinical environment is recommended, attention should be paid to respiratory and cardiovascular functions. Gastric lavage or activated charcoal is only useful when performed soon after ingestion.
Hemodialysis is of no value due to the large volume of distribution of zopiclone. Flumazenil may be a useful antidote; however, flumazenil administration may contribute to the appearance of neurological symptoms (agitation, anxiety, convulsionsand emotional lability). Intravenous fluids should be administered as needed.
Contraindications:
Imovane (Zopiclone) is contraindicated in patients with:
Warnings and precautions:
Avoid to take Zopiclone (Imovane) tablets if you have:
Adverse reactions, side effects:
Most common zopiclone adverse reactions: headaches, dry mouth, bitter taste in your mouth, drowsiness.
Less common side effects include: heartburn, nausea, vomiting and/or diarrhoea, change in appetite, stomach pain, rash, agitation, depression, confusion, anxiety, dizziness, blurred vision, impotence, sleep walking or other unusual behaviours (such as driving, eating, making a phone call, or having sex etc.) while not being fully awake.
To report suspected adverse reactions of Imovane (Zopiclone) tablets, contact Sanofi pharmaceutical company or your local FDA.
Drug interactions:
The risk of zopiclone drug interaction arising from displacement of bound drug is low.
Be careful wneh you use this medication with:
Use in specific populations:
Elderly (65 years of age or more), debilitated patients and/or patients with liver, kidney, or chronic respiratory problems should start with 3.75 mg (one-half of a 7.5 mg tablet) at bedtime just before retiring. The dose in elderly, debilitated patients and/or patients with liver or kidney problems is not to exceed 5 mg.
Drug abuse and dependence:
Use of sedative/hypnotics agents like zopiclone may lead to the development of physical and psychological dependence or abuse. The risk of dependence or abuse is increased with the dose and duration of treatment, if used with alcohol or other psychotropics, in patients with a history of alcoholism and/or drug abuse or in patients with marked personality disorders. Interdose daytime anxiety and rebound anxiety may increase the risk of dependency in zopiclone treated patients.
Pregnancy categories:
Salts and other forms:
Synonyms, international and chemical names:
Brands, generics, trade names:
References:
Revised: January 2022
"We provided some exciting changes to the study plan within a couple of weeks of treatment dates and the team stepped up, as usual, and put a plan into place to give us the highest chance of success utilizing the criteria we requested."
Our expert preclinical Surgeons and Interventionalists can assist with human factors assessments and evaluating prototypes for your GLP or nonGLP preclinical studies.
Preclinical Testing Solutions
Throughout the
Product Innovation Cycle.
About Us
Expertise
Testing Services
Customer Support
Copyright © 2015 - 2022 Surpass, Inc. All Rights Reserved.
